About
Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a research and development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million.
Position in the VCSift Database
- • 4,609 investors in VCSift focus on the biotech sector.
- • 110 investors are based in Nanjing, Jiangsu, China.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- biotech
- Location
- Nanjing, China
Contact Information
linkedin.com/in/••••••••
Find more investors like Simcere
Search Investors